Related Experiment Video
Updated: Feb 26, 2026
10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
10.0K
IL-4Rα Inhibitor for Atopic Disease
Howard Y Chang1, Kari C Nadeau1
1Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Cell
|July 15, 2017
Summary
Dupilumab, a monoclonal antibody, effectively treats atopic dermatitis by blocking key inflammatory cytokines IL-4 and IL-13. This targeted therapy offers a new option for eczema management.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Atopic dermatitis (eczema) is a chronic inflammatory skin condition driven by type 2 immune responses.
- Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are key cytokines mediating type 2 inflammation.
- Targeting these cytokines offers a potential therapeutic strategy for atopic dermatitis.
Purpose of the Study:
- To describe dupilumab, a novel biologic agent targeting the IL-4 receptor alpha subunit.
- To highlight the mechanism of action of dupilumab in blocking IL-4 and IL-13 signaling.
- To provide information on the approval and application of dupilumab for atopic dermatitis treatment.
Main Methods:
- Dupilumab is a fully human monoclonal antibody (IgG4).
- It specifically targets the alpha subunit (IL-4Rα) shared by IL-4 and IL-13 receptors.
- This blockade inhibits downstream signaling pathways of these critical cytokines.
Main Results:
- Dupilumab effectively inhibits the IL-4 and IL-13 signaling pathways.
- These pathways are central to the type 2 inflammatory response implicated in atopic dermatitis.
- Clinical efficacy of dupilumab in treating atopic dermatitis has been demonstrated.
Conclusions:
- Dupilumab represents a significant advancement in the treatment of atopic dermatitis.
- By targeting key drivers of type 2 inflammation, it offers a targeted therapeutic approach.
- The approval of dupilumab provides a new biologic option for patients with moderate-to-severe eczema.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.0K
01:24T Cell Types and Functions
2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
01:30Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K